Alnylam, Fox Chase Cancer Center, Dharmacon, Sigma-Aldrich, Beijing Superior Chemicals and Instruments | GenomeWeb

Alnylam CEO Adopts Plan to Sell Up to 7 Percent of His Stake in Company

Alnylam Pharmaceuticals said last week that President and CEO John Maraganore has adopted a prearranged stock trading plan under which he may sell approximately 84,000 shares of the company stock that he owns.

The shares represent approximately 7 percent of Maraganore's total ownership of Alnylam stock and stock option holdings. Alnylam said that Maraganore adopted the plan for "personal financial reasons."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.